Researchers from Nagoya University Graduate School of Medicine have explored a significant connection between cancer cells' ability to manage replication stress and the Taurine Upregulated Gene 1 (TUG1). The study showed that by targeting the TUG1 gene with a specialized drug, brain tumor growth in mice could be controlled. This finding hints at a novel approach for addressing aggressive brain tumors, including glioblastomas.
“These findings have the potential to be translated into therapeutic applications, as TUG1 is highly expressed in glioblastoma,” remarked lead researcher Professor Yutaka Suzuki. “In this study, we successfully developed a therapeutic drug named TUG1-DDS, which selectively targets TUG1. It significantly suppressed tumor growth and improved survival, especially when administered in combination with the standard treatment of temozolomide. Therefore, it is a potentially effective therapeutic agent for treating glioblastoma.”
To fathom TUG1's potential effectiveness against formidable brain cancers, the study highlighted the mechanisms by which cancer manipulates the standard processes of host cells to foster conditions conducive to cancer cell growth. Crucial processes like replication are hijacked by cancer for its benefit.
During cell division, the DNA is replicated so that both resultant cells possess the complete genetic information. During this, the double-stranded DNA is separated into two single strands. Each of these acts as a template to produce two identical copies by merging with RNA. This process involves a hybrid structure of DNA and RNA known as an R-loop, which plays a role in unwinding the DNA.
Cancer cells, to foster conditions beneficial for them, disrupt the typical DNA replication process. This induces what's termed replication stress (RS), causing DNA strands to break and an increase
in unpaired single DNA strands. This activity creates genome instability, promoting tumor growth.
However, this heightened activity can be counterproductive for cancer cells. RS and R-loop accumulation can lead to cancer cell death. To manage their genome, cancer cells employ long noncoding RNAs (lncRNAs). This enables them to fix the DNA damage they accrue and discard extraneous R-loops.
The study, led by Yutaka Kondo and Miho Suzuki, zeroed in on the role of the lncRNA TUG1. Their research determined that TUG1, along with two proteins (DHX9 and RPA32), suppresses harmful R-loops. The interaction between TUG1, RPA, and DHX9 is pivotal for regulating R-loops, especially in regions prone to DNA damage and mutations. This significant discovery was published in Nature Communications.
Additionally, the researchers observed a swift up-regulation of TUG1 in response to RS. A reduction in TUG1 expression within cancer cells led to pronounced DNA damage and cell death. Dr. Suzuki mentioned “It was exciting to see the rapid increase in expression of TUG1 in response to replication stress. Normally, it takes several hours or more for proteins to increase in response to stimuli, but RNA can be synthesized rapidly. That TUG1, an RNA molecule, increases immediately in response to replication stress indicates that it is necessary to respond quickly to critical situations.”
Dr. Kondo added that these findings hold promise for developing treatments for other cancers. He said, “TUG1 inhibitors have also been found to be effective in other types of cancer, such as pancreatic cancer and ovarian cancer. Therefore, our novel treatment, TUG1-DDS, could also be effective in other cancer types with expression of TUG1.”
“These findings have the potential to be translated into therapeutic applications, as TUG1 is highly expressed in glioblastoma,” remarked lead researcher Professor Yutaka Suzuki. “In this study, we successfully developed a therapeutic drug named TUG1-DDS, which selectively targets TUG1. It significantly suppressed tumor growth and improved survival, especially when administered in combination with the standard treatment of temozolomide. Therefore, it is a potentially effective therapeutic agent for treating glioblastoma.”
To fathom TUG1's potential effectiveness against formidable brain cancers, the study highlighted the mechanisms by which cancer manipulates the standard processes of host cells to foster conditions conducive to cancer cell growth. Crucial processes like replication are hijacked by cancer for its benefit.
During cell division, the DNA is replicated so that both resultant cells possess the complete genetic information. During this, the double-stranded DNA is separated into two single strands. Each of these acts as a template to produce two identical copies by merging with RNA. This process involves a hybrid structure of DNA and RNA known as an R-loop, which plays a role in unwinding the DNA.
Cancer cells, to foster conditions beneficial for them, disrupt the typical DNA replication process. This induces what's termed replication stress (RS), causing DNA strands to break and an increase
in unpaired single DNA strands. This activity creates genome instability, promoting tumor growth.
However, this heightened activity can be counterproductive for cancer cells. RS and R-loop accumulation can lead to cancer cell death. To manage their genome, cancer cells employ long noncoding RNAs (lncRNAs). This enables them to fix the DNA damage they accrue and discard extraneous R-loops.
The study, led by Yutaka Kondo and Miho Suzuki, zeroed in on the role of the lncRNA TUG1. Their research determined that TUG1, along with two proteins (DHX9 and RPA32), suppresses harmful R-loops. The interaction between TUG1, RPA, and DHX9 is pivotal for regulating R-loops, especially in regions prone to DNA damage and mutations. This significant discovery was published in Nature Communications.
Additionally, the researchers observed a swift up-regulation of TUG1 in response to RS. A reduction in TUG1 expression within cancer cells led to pronounced DNA damage and cell death. Dr. Suzuki mentioned “It was exciting to see the rapid increase in expression of TUG1 in response to replication stress. Normally, it takes several hours or more for proteins to increase in response to stimuli, but RNA can be synthesized rapidly. That TUG1, an RNA molecule, increases immediately in response to replication stress indicates that it is necessary to respond quickly to critical situations.”
Dr. Kondo added that these findings hold promise for developing treatments for other cancers. He said, “TUG1 inhibitors have also been found to be effective in other types of cancer, such as pancreatic cancer and ovarian cancer. Therefore, our novel treatment, TUG1-DDS, could also be effective in other cancer types with expression of TUG1.”